W
WAVEMAN · COMPANY
CMMB · Chemomab Therapeutics Ltd.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

CMMB

Chemomab Therapeutics Ltd.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001534248
ACTIVIST 13DC-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$13.7K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
5
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$13.7K over 180 days
-$6.5K over 90 days
more than 68% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
5 funds added or opened last quarter
below 96% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 2.2 days to cover · settled 2026-07-31
below 92% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
HBM Healthcare Investments (Cayman) Ltd. disclosed a 5%+ stake (12.5%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -8.7%
-8.7%12M
-56%-33%-10%+13%2025-092025-102025-122026-032026-052026-072026-09 2026-05-29 · Mor George Adi bought $10.2K2026-05-29 · Mor George Adi bought $10.0K2026-08-27 · Cohen Neil Harris sold $3.7K2026-08-28 · Cohen Neil Harris sold $2.8K2026-07-16 · HBM Healthcare Investments (Cayman) Ltd. filed a 5%+ stake (12.5%)
INSIDER BUYINSIDER SELL13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows a net $13.7K bought by insiders over 180 days, 5 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Chemomab Therapeutics Ltd. insiders bought a net $13.7K of stock across 30 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Cohen Neil Harris
Director
SELL
2026-08-28
1,000.0
$2.8K
Cohen Neil Harris
Director
SELL
2026-08-27
1,304.0
$3.7K
Mor George Adi
Chief Executive Officer
BUY
2026-05-29
4,878.0
$10.0K
Mor George Adi
Chief Executive Officer
BUY
2026-05-29
4,926.0
$10.2K
OrbiMed Israel BioFund GP Limited Partnership
—
SELL
2023-01-03
70,524.0
$318.1K
30 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 25 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
CITADEL ADVISORS LLC
95,311.0 sh
$154.4K
ADAR1 Capital Management, LLC
80,000.0 sh
$129.6K
KESTRA PRIVATE WEALTH SERVICES, LLC
61,710.0 sh
$100.0K
Ikarian Capital, LLC
51,793.0 sh
$83.9K
RHUMBLINE ADVISERS
30,529.0 sh
$49.5K
5%+ owners
13D = intent to influence · 13G = passive
HBM Healthcare Investments (Cayman) Ltd.
ACTIVIST 13D · 2026-07-16
12.5%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-112.0M$-103.0M——
NET INCOME$-9.0M$-13.9M$-24.2M$-27.6M
EPS (DILUTED)0.020.040.100.12
OPERATING CASH FLOW$-11.1M$-15.4M$-23.6M$-20.4M
CASH$7.6M$6.1M$9.3M$13.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →